Wednesday, October 26, 2022
Biostage, Inc., a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway, today announced the issuance of a U.S. patent that protects the extension of the use of Biostage's technology from hollow tubes to patches. Biostage expects this new technology to enable it treat fistulas (holes), strictures (narrowings) or damage to the esophagus such as from gastero-esophageal reflux disease, or GERD, as well as damage and disease in other parts of the gastero-intestinal tract such as the stomach and intestine. This new technology is known as the Biostage Tissue Patch.
The Biostage Tissue Patch is a patch of fibrous material that is seeded with the patient's own mesenchymal stromal cells that are derived from a biopsy of abdominal adipose (fat) tissue. The patch can be made using Biostage's proprietary, and patented, electrospinning technology in any size, shape, or geometry to match the internal surface of a hollow organ. The Biostage Tissue Patch is a temporary cell-delivery device that administers a large dose of the patient's own wound-healing cells to the site where the diseased or damaged tissue was removed. The cells stimulate the body's natural wound-healing process, and the scaffold supports the tissue regeneration and protects the wound from contamination and abrasion. The scaffold is temporary and is removed using a minimally invasive endoscopic procedure after the initial healing is complete.
David Green, Biostage's founder, Chair of the Board and interim Chief Executive Officer commented, "We are very pleased with this new patent because it could extend Biostage's breakthrough therapy for regenerating the esophagus due to cancer, trauma or birth defects to the treatment of benign conditions of the esophagus as well as to the regeneration of other hollow organs including the stomach and intestine."
Dr. Bill Fodor, Biostage's Chief Scientific Officer, commented, "The issuance of this key patent protects Biostage's cell delivery technology to include endoluminal repair without the need for major surgery, in a variety of organ structures. Establishing a non-surgical product portfolio further expands the medical utility for our targeted cell delivery approach."
The new patent is titled, "METHOD AND DEVICE FOR IN VIVO TISSUE REGENERATION ON THE INTERIOR SURFACE OF HOLLOW ORGANS". It was issued on October 11, 2022 by the USPTO as patent number 11,464,887 B2.